Our Portfolio
We have a growing portfolio aimed at addressing the unmet needs of infectious diseases and other emerging diseases. We’re focused on developing and delivering vaccines across these areas:
Smallpox and Ebola*
Safeguarding the population against biosecurity threats and outbreaks
Rabies, TBE & Monkeypox
Protection at home and abroad
RSV
Advancing new vaccine technologies to address unmet medical need
COVID-19
Advancing the development of a next-generation vaccine
Grey box indicates products in development, not yet approved.
RSV, Respiratory Syncytial Virus; TBE, tick-borne encephalitis.
*in collaboration with Janssen
Our History
Founded in 1994, Bavarian Nordic is committed to protecting the population against life-threatening diseases, through the development and manufacturing of innovative life-saving vaccine technologies.
Some of Our Key Milestones…
We have collaborated with the US government for nearly 20 years, applying our innovative vaccine platform technology to support and protect US citizens from biosecurity threats and outbreaks. We have also successfully partnered with Janssen on an approved Ebola vaccine.
Whilst proud of our achievements in vaccine development over the past 25 years, we are focused on the future. Right now, we are working on bringing patients around the globe an even greater degree of protection from infectious diseases.
OUR MISSION
We aspire to save and improve lives by unlocking the power of the immune system. Immunisation positively impacts, directly or indirectly, 14 of the 17 United Nations Sustainable Development Goals (SDGs) that support the 2030 Agenda for Sustainable Development. We are committed to growing responsibly whilst simultaneously supporting the of ensuring healthy lives and fostering innovation.
Our focus is always on the patient which is why we continue to provide prescribers and healthcare professionals with support for medical and disease education to help improve awareness.
With our recent acquisition of well-known and trusted vaccine products for rabies and tick-borne encephalitis from GSK, we are committed to expanding into new disease areas, and advancing the field of infectious diseases, such as COVID-19 and respiratory syncytial virus, through new vaccine technologies.
